U.S. Stock Market Midday Update

Mustang Bio rose 31.92%, with increased trading volume. Based on recent important news:

1. On July 8, Mustang Bio received FDA orphan drug designation, driving the stock price up 234%. This designation provides tax incentives and market exclusivity for its experimental cancer therapy MB-101.

2. On July 7, MB-101 performed well in a Phase 1 trial, with 50% of patients showing stable or improved conditions.

3. On July 8, the global oncology market growth expectations were withdrawn, which did not negatively impact the stock price.

Stocks with High Trading Volume in the Industry

Kazia Therapeutics rose 41.70%, with increased trading volume. Based on recent important news:

1. On July 9, Kazia Therapeutics released new research results showing significant progress in clinical trials for its new drug, driving the stock price up 41.70%.

2. On July 8, the market expressed optimism about Kazia's financial report, expecting its future profitability to enhance, further stimulating the stock price.

3. On July 7, industry analysts upgraded Kazia's rating, believing its innovative capabilities in cancer treatment will lead to long-term growth.

Stocks with High Market Capitalization in the Industry

Abbvie rose 0.21%, with increased trading volume. Based on recent important news:

1. On July 9, progress was made in the application of CAR-T cell therapy for autoimmune diseases, potentially leading to unexpected therapeutic effects, driving Abbvie's stock price up.

2. On July 7, analysts stated that Abbvie is not on the current best investment list, although rated as a moderate buy, the impact is limited.

3. On July 6, long-term positive news in the innovative drug industry led to institutional accumulation, enhancing market confidence